Tesamorelin: what a cognition trial found

A 2026 double-blind pilot trial tested whether ten weeks of low-dose tesamorelin (1 mg of the growth hormone-releasing hormone analog, given by subcutaneous injection) could shift cognitive performance or brain connectivity in adults whose cognition ranged from normal to mild cognitive impairment. On standard statistical tests of the pre-specified outcomes, the answer was no significant change on any primary measure^[1]. When the research team layered on a machine learning analysis, they detected potential treatment-related differences in two brain regions linked to attention and executive function.

This article covers what the trial actually measured, what the results mean, where this sits in the broader tesamorelin cognition literature, and what remains unknown. It is not medical advice.

What the trial did

Stewart, French, Wright and colleagues enrolled 22 participants in a randomised, double-blind, placebo-controlled pilot published in eNeurologicalSci in 2026 (PMID 42382101)^[1]. Participants received either 1 mg of GHRH (tesamorelin) or placebo daily for ten weeks. The team tracked body composition, fatigue, sleep quality, physical performance, glucose tolerance, cognitive function, and brain morphometry and functional connectivity through neuroimaging.

The population is notable: adults with cognition ranging from normal to mild cognitive impairment (MCI). This puts the study in a different setting from the FDA-approved use of tesamorelin for HIV-associated lipodystrophy, and it positions the trial in the growing literature asking whether GHRH might slow or partially reverse early cognitive decline.

What the conventional statistics showed

On pre-specified outcome measures, low-dose GHRH treatment was not directly linked with significant changes in any study measure^[1]. That includes the cognitive assessments. This result is consistent with the trial being underpowered: 22 participants cannot reliably detect a modest cognitive effect in a ten-week window. The authors acknowledge this limitation directly.

The 2012 randomised trial by Baker and colleagues provides useful context. That study enrolled 152 adults, including 66 with MCI, and ran for 20 weeks at 1 mg daily of tesamorelin. It reported favorable effects on executive function and a trend toward improved verbal memory, with gains present in both the MCI and the cognitively normal groups^[2]. The comparison between the two trials suggests that duration and sample size both matter when measuring cognitive effects of GHRH.

Where the machine learning signal appeared

The 2026 Stewart trial added a machine learning analysis on top of the conventional statistics. That analysis identified potential treatment-related differences in two brain regions: the right anterior cingulate cortex and the left superior frontal occipital fasciculus^[1]. The authors describe the finding as hypothesis-generating. Their conclusion is that coupling cognitive assessments and neuroimaging with machine learning may improve the ability to detect subtle treatment effects in small samples, which could inform the design of larger future trials.

The anterior cingulate cortex is involved in attention, conflict monitoring, and error detection. The superior frontal occipital fasciculus is a white-matter tract connecting frontal and occipital brain regions. Changes in either structure are plausibly relevant to executive processing, though what observed differences in a 22-person pilot mean for clinical outcomes is not clear at this stage.

How this fits the tesamorelin cognition literature

Tesamorelin is FDA-approved under the brand Egrifta for HIV-associated lipodystrophy, not for any cognitive indication^[3]. The off-label interest in cognition rests partly on the observation that GHRH stimulates IGF-1 release, and IGF-1 has known effects on neurogenesis and synaptic maintenance. The clinical evidence is mixed across three trials now.

A 2025 Phase 2 randomised trial by Ellis and colleagues tested tesamorelin 2 mg daily for six months in 73 people with HIV, abdominal obesity, and neurocognitive impairment^[4]. The tesamorelin arm showed a trend toward improved neurocognitive performance (mean change 0.146, p=0.060), but the between-group difference was not statistically significant (p=0.673). Higher IGF-1 levels did not predict better cognitive outcomes. The authors concluded there was no clear benefit from short-term abdominal obesity reduction with tesamorelin on neurocognitive impairment.

Across the three trials, a pattern holds: GHRH/tesamorelin produces a detectable cognitive signal in some designs but not others. Effect sizes appear modest and depend on duration, dose, population, and which cognitive domain is being measured.

What we do not yet know

The 2026 Stewart trial ran for ten weeks in 22 people. It cannot answer whether longer durations, as in the 20-week Baker trial, or higher doses would shift the brain-connectivity picture. The machine learning findings from the anterior cingulate and the fasciculus need replication in a powered sample before they count as treatment effects rather than noise in a small dataset.

A second open question is the mechanism. GHRH could affect cognition through direct brain receptor activity, through elevated IGF-1, or through improvements in slow-wave sleep (GHRH promotes slow-wave sleep, which has its own role in memory consolidation). The Stewart trial measured sleep alongside cognition, but separating those pathways in 22 participants is not possible.

None of the trials to date were sized to look at dementia incidence, long-term cognitive trajectory, or hard neurodegeneration endpoints. The tesamorelin cognition literature is still in the exploratory phase.

Regulatory picture and standard disclaimer

Tesamorelin holds one FDA-approved indication: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The EMA marketing authorisation application for Egrifta was withdrawn in 2012 and has not been resubmitted. There is no approved cognitive or neurological indication in any jurisdiction. Any use in MCI or cognitive contexts is off-label and investigational. The full regulatory picture by country is on the tesamorelin overview page.

This article is for educational and journalistic purposes only and does not constitute medical advice. Tesamorelin may be classified as a prescription medicine or a research chemical depending on your country. Always consult a qualified healthcare professional before considering any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.